MiNK Therapeutics Inc. (INKT) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Per the Roarable RQD rating, INKT scores 43 out of 100, a letter grade of D-, with the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars, the fundamental cash engine scores 9 of 20 (ROIC of -35%; FCF yield of -10.68%), indicating the business is not currently generating returns on capital or free cash flow. Whale 13F flow scores 9 of 20, reflecting institutional accumulation and options positioning that the rating treats as a modest support rather than a strong signal. Insider conviction scores 3 of 20, the weakest pillar, based on SEC Form 4 and Congressional PTR cluster flow. Macro regime fit scores 12 of 20, with a beta of 1.0 and sector sensitivity noted. Forensic balance sheet scores 10 of 20, citing an Altman Z of 2.5, a Piotroski F of 2 out of 9, and a Debt/Equity of 0.5.

For a prospective investor, the upside case rests on the stock's price recovery within its 52-week range and on the positive analyst-related headline in the news feed, but the rating frames the valuation as unsupported by current cash generation. The tradeoff is that the stock trades at a market capitalization of $55.5M with no reported earnings-based valuation multiples available, so the price cannot be benchmarked against earnings. The weak insider and fundamental pillars suggest the risk is concentrated in the balance sheet and cash burn rather than in market sentiment alone.

Per the SEC financials, the company reported net losses in every listed period, with the FY 2025 net loss at $-12.5M and operating loss at $-12.6M. Gross, operating, and net margins are each 0% per the market data, consistent with no reported revenue. Per the Roarable RQD rating, ROIC is -35%, the Altman Z-Score is 2.5, and the Piotroski F-Score is 2 out of 9. Cash rose from $4.6M in FY 2024 to $13.4M in FY 2025, while Debt/Equity is 0.5 per the rating, with the reported debt line itself listed as N/A.

Per the recent news feed, the top item is a GREEN-flagged CATALYST headline reporting that B. Riley Securities maintained a Buy rating and raised its target price to $50. A YELLOW-flagged MARKET WIRE item references a seasonal returns chart for a related company and does not describe INKT-specific fundamentals. A RED-flagged RISK WATCH item is titled "Price Dynamics and Execution-Aware Positioning," and the remaining items are YELLOW-flagged MARKET WIRE reports covering price action and general U.S. stock listings. Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.

• What specific products or clinical programs drive the company's operations, given that no business description beyond sector and industry is provided?
• What are the debt obligations and their terms, since the debt line is N/A while Debt/Equity is cited as 0.5?
• What is the company's cash runway at the current burn rate, given FY 2025 FCF of $-5.9M against $13.4M cash?
• What is the basis for the B. Riley $50 target relative to the $10.53 price, and what assumptions underlie it?
• Which 13F filers and insider transactions make up the cited accumulation and cluster flow signals?